Pure Global

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B - Trial NCT06263959

Access comprehensive clinical trial information for NCT06263959 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fujian Akeylink Biotechnology Co., Ltd. and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06263959
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06263959
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Study Focus

Chronic Hepatitis B

GST-HG131

Interventional

drug

Sponsor & Location

Fujian Akeylink Biotechnology Co., Ltd.

Beijing, China

Timeline & Enrollment

Phase 2

Dec 29, 2023

Nov 01, 2024

45 participants

Primary Outcome

Change from Baseline in HBsAg levels

Summary

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the
 safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B

ICD-10 Classifications

Acute hepatitis B
Chronic viral hepatitis B without delta-agent
Acute delta-(super)infection in chronic hepatitis B
Chronic viral hepatitis B without delta-agent : other and unspecified phase
Chronic viral hepatitis B without delta-agent : immune-tolerant phase

Data Source

ClinicalTrials.gov

NCT06263959

Non-Device Trial